IMMX
Immix Biopharma, Inc.
5.94
-0.27-4.27%
Dec 16, 4:00:01 PM EST

Upcoming Earnings 

Report date
≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap
313.01M
P/E (TTM)
-
Basic EPS (TTM)
-0.77
Dividend Yield
0%

Recent Filings

About 

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

CEO
Dr. Ilya Rachman M.B.A., M.D., Ph.D.
IPO
12/16/2021
Employees
18
Sector
Healthcare
Industry
Biotechnology